Structure Therapeutics down ahead of weight-loss drug data

Shares of Structure Therapeutics GPCR.O falls 1.4% to $34.1 premarket

The drug developer on December 8 is set to release data from a study evaluating its experimental drug aleniglipron, a once-daily oral for the treatment of obesity

The current landscape for obesity treatments includes Danish drugmaker Novo Nordisk's NOVOb.CO Wegovy and Eli Lilly's LLY.N Zepbound both of which dominate the market

Viking Therapeutics' experimental weight-loss pill VK2735 previously failed to surpass Wall Street expectations in August

As of last close, GPCR stock was up 27.4% YTD